Preparation methods of tofacitinib citrate intermediate and tofacitinib citrate

A technology of tofacitinib and citric acid, which is applied in the preparation of tofacitinib citrate and the field of tofacitinib citrate intermediates, which can solve the problems of high catalyst consumption and catalyst poisoning

Inactive Publication Date: 2020-01-10
江苏海悦康医药科技有限公司
View PDF5 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The synthesis process of this compound has been improving, and the early process has great disadvantages
[0008] The synthetic route of the document Org.Process Res.Dev., 09, 2005, 51-56 has the...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation methods of tofacitinib citrate intermediate and tofacitinib citrate
  • Preparation methods of tofacitinib citrate intermediate and tofacitinib citrate
  • Preparation methods of tofacitinib citrate intermediate and tofacitinib citrate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] A preparation method of tofacitinib citrate, comprising the following steps:

[0073] One, the preparation of tofacitinib citrate intermediate; The described tofacitinib citrate intermediate is (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine double hydrochloride;

[0074] 2. N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-p-toluenesulfonyl-pyrrolo[2,3-d]pyrimidine -The preparation of 4-amine; Concretely comprise the following steps:

[0075] A. Mix 10.0kg purified water, 2.6kg acetonitrile, 1.7kg (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride and 2.3kg potassium carbonate, stir to dissolve;

[0076] B. Add 1.8kg of 4-chloro-7-p-toluenesulfonyl-pyrrolo[2,3-d]pyrimidin-4-amine to the result of the previous step in several times, and raise the temperature to 75-85°C for 10 hours to carry out HPLC detection;

[0077] C. Cool down to 20-30°C and keep stirring for 2 hours, filter with suction, wash the filter cake with 3kg of purified water, and set...

Embodiment 2

[0095] On the basis of Example 1, the preparation method of the tofacitinib citrate intermediate (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride Specifically:

[0096]

[0097] (1) Preparation of N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidin-3-yl)acetamide; specifically comprising the following steps:

[0098] A. Add 2.2kg of 3-amino-4-methyl-pyridine into 15kg of dichloromethane and 22kg of toluene, cool down to 0-10°C, add 1.7kg of acetyl chloride dropwise, and react at 20-25°C for 10 hours; Below ℃, add aqueous sodium hydroxide solution dropwise, adjust the pH to 8-9, separate the lower aqueous phase; concentrate the organic phase under reduced pressure to a volume of 23-25L;

[0099] B. Add 1.9 kg of benzyl chloride to the resultant of the previous step, heat up to 70-80°C for reaction, and separate the dichloromethane distilled during the heating process; cool down to 0-10°C after the reaction;

[0100] C. Control the temperature below 10°C, and add...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses preparation methods of a tofacitinib citrate intermediate and tofacitinib citrate. The preparation method of the tofacitinib citrate intermediate comprises: preparing N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidine-3-yl)acetamide by using 3-amino-4-methyl-pyridine, acetyl chloride, benzyl chloride and sodium borohydride as raw materials; preparing 1-benzyl-N,4-dimethylpiperidine-3-amine by using the N-(1-benzyl-4-methyl-1,2,5,6-tetrahydropiperidine-3-yl)acetamide, hydrochloric acid, methylamine and sodium borohydride as raw materials; and carrying out resolution and dissociation on the 1-benzyl-N,4-dimethylpiperidine-3-amine, and carrying out salt forming with hydrochloric acid to obtain the product. The invention provides the new tofacitinib citrate intermediatepreparation method, wherein the use amount of the catalytic hydrogenation catalyst is reduced in the preparation process of tofacitinib citrate so as to reduce the cost, and the generation of N-alkylated impurities can be well controlled by adopting the isopropanol/water mixed solvent.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to a tofacitinib citrate intermediate and a preparation method of tofacitinib citrate. Background technique [0002] The chemical name of tofacitinib citrate is 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino ]-piperidin-1-yl}-3-oxo-propionitrile, 2-hydroxypropane-1,2,3-tricarboxylate (1:1), the structural formula is as follows: [0003] [0004] Tofacitinib citrate is a Janus kinase (JAK) inhibitor, which can effectively inhibit the activity of JAK1 and JAK3, and block the signal transduction of various inflammatory cytokines. Tofacitinib citrate was developed by Pfizer, and in 2012, it was recognized by the FDA as a breakthrough therapy, and it was marketed for the treatment of rheumatoid arthritis that is intolerant to methotrexate treatment. [0005] The difficulty in the synthesis process of tofacitinib citrate is the dual-chiral center-substituted piperidine ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D211/56C07D487/04
CPCC07D211/56C07D487/04
Inventor 裴欣宇陈泽明谢荣光
Owner 江苏海悦康医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap